Related Experiment Videos
The effect of suramin, tumor necrosis factor and interferon gamma on human prostate carcinoma
1Urologic Oncology Section, National Cancer Institute, Bethesda, Maryland 20892.
Abstract:
Suramin, an antiparasitic agent which has been shown to block the stimulatory effect of growth factors on certain cancers, is currently being evaluated in clinical trials and as an antineoplastic agent in patients with advanced prostate carcinoma. Preliminary studies suggested that suramin inhibits the growth in vitro of human prostate carcinoma. The present study was performed in order to evaluate the effect of suramin, recombinant human tumor necrosis factor (TNF), interferon gamma and the combination of suramin plus TNF or interferon gamma on proliferation of PC-3, a human, hormone unresponsive prostate carcinoma cell line. In medium containing 2% fetal calf serum (FCS) suramin, at doses of 10 microM, 30 microM and 100 microM (levels readily achievable in humans) inhibited proliferation of PC-3. TNF, at a concentration of 500 units/ml., induced an approximately 50% inhibition of growth of PC-3. The combination of suramin plus TNF induced a greater inhibition of growth than did either agent alone, even at the low dose of 10 microM suramin. Interferon gamma, 500 units/ml., inhibited PC-3 growth. However, the combination of interferon gamma plus suramin (30 microM) induced less inhibition of proliferation than did interferon gamma alone. These results may serve as a rationale for clinical trials employing the combination of TNF plus suramin in patients with advanced prostate carcinoma.
Insights
Suramin and tumor necrosis factor (TNF) show promise in inhibiting prostate cancer cell growth. Combining suramin with TNF demonstrated enhanced anti-cancer effects compared to individual treatments.
Area of Science:
- Oncology
- Pharmacology
Background:
- Suramin, an antiparasitic drug, exhibits antineoplastic properties by inhibiting growth factor signaling in various cancers.
- It is under investigation for advanced prostate carcinoma treatment.
- Preliminary data suggests suramin inhibits human prostate carcinoma growth in vitro.
Purpose of the Study:
- To evaluate the effects of suramin, recombinant human tumor necrosis factor (TNF), and interferon gamma (IFN-γ) on the proliferation of the PC-3 human prostate carcinoma cell line.
- To assess the combined effects of suramin with TNF or IFN-γ on PC-3 cell proliferation.
Main Methods:
- PC-3 cells were treated with varying concentrations of suramin (10-100 microM), TNF (500 units/ml), and IFN-γ (500 units/ml) in 2% fetal calf serum (FCS).
- The combination of suramin with either TNF or IFN-γ was also tested.
- Cell proliferation was measured to determine the inhibitory effects of each agent and their combinations.
Main Results:
- Suramin inhibited PC-3 cell proliferation at doses of 10, 30, and 100 microM.
- TNF alone inhibited PC-3 cell growth by approximately 50%.
- The combination of suramin plus TNF showed greater growth inhibition than either agent alone, even at low suramin doses (10 microM).
- IFN-γ inhibited PC-3 growth, but the combination of IFN-γ plus suramin (30 microM) resulted in less inhibition than IFN-γ alone.
Conclusions:
- The combination of TNF and suramin demonstrates synergistic anti-proliferative effects on hormone-unresponsive prostate cancer cells (PC-3).
- These findings support the potential clinical application of combining TNF and suramin for treating advanced prostate carcinoma.
- The combination of IFN-γ and suramin did not show enhanced efficacy compared to IFN-γ alone in this model.